Trial Parameters
Brief Summary
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: * Written and signed informed consent * Histopathologically and/or cytologically newly-diagnosed SCLC * Measurable disease on CT scans * Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide Exclusion Criteria: * Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * Treatment with any other investigational agent